The veopoz market research report is one of a series of new reports that provides veopoz market statistics, including the veopoz industry's global market size, regional shares, competitors with a veopoz market share, detailed veopoz market segments, market trends and opportunities, and any further data you may need to thrive in the veopoz industry. This veopoz market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The growth in the forecast period can be attributed to increasing demand for targeted cancer therapies, growth in prevalence of chronic lymphocytic leukemia (CLL) and follicular lymphoma, expanding adoption of combination therapies, rising healthcare investments in oncology treatments, increasing awareness of personalized medicine, and potential for expanding approvals and indications for veopoz in other cancers. Major trends in the forecast period include advancements in formulation, development of combination therapies, advancements in patient support programs, advancements in cancer research and drug development, and advancements in cancer treatments.
The growing demand for personalized medicine is expected to drive the growth of the Veopoz market. Personalized medicine, also known as precision medicine, is an approach to healthcare that customizes treatment and medical decisions based on the individual characteristics of each patient. This demand is being fueled by advancements in genomics and biotechnology, which enable more targeted and effective treatments that improve patient outcomes and reduce side effects. Veopoz (Pozelimab-bbfg) serves as a personalized medicine by selectively inhibiting complement factor C5 activation, offering a treatment tailored to individual patient profiles, genetic factors, and the severity of diseases involving complement-mediated conditions. For example, in February 2024, the Personalized Medicine Coalition reported that in 2023, personalized medicines accounted for more than one-third of FDA drug approvals, including 16 new treatments for rare diseases, which was more than double the number approved in 2022. As a result, the growing demand for personalized medicine is driving the Veopoz market forward.
A significant trend in the Veopoz market is the expansion of its approved indications, which increases the drug's market reach and therapeutic applications. By broadening its approved indications, the drug can target a larger patient population, further boosting its market share within the biologics and immunology sectors. For instance, in August 2023, Regeneron Pharmaceuticals received FDA approval for Veopoz as the first treatment for CHAPLE disease, an ultra-rare hereditary disorder affecting both adults and children over one year of age. Veopoz is a fully human monoclonal antibody specifically designed to target complement factor C5, aiming to regulate an overactive immune response. This approval marked a significant milestone for Regeneron Pharmaceuticals as their tenth FDA-approved medicine and addressed critical issues related to pre-approval inspections for another product.
In August 2023, Regeneron Pharmaceuticals entered into a partnership with Orsini Specialty Pharmacy, a US-based independent pharmacy that specializes in rare diseases and gene therapies. As part of the agreement, Orsini became the exclusive specialty pharmacy for Veopoz, helping to expand access to this life-changing treatment for patients with ultra-rare conditions who previously had limited options. Through this collaboration, Orsini Specialty Pharmacy plays a crucial role in supporting patients with rare conditions, ensuring they have access to this important treatment.
The key company operating in the veopoz market is Regeneron Pharmaceuticals Inc.
North America was the largest region in the veopoz market in 2024. The regions covered in veopoz report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the veopoz market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Veopoz (pozelimab-bbfg) is a human monoclonal IgG4 antibody that specifically targets and inhibits complement factor C5 in the complement pathway. It helps modulate immune responses in diseases where complement dysregulation plays a critical role, such as paroxysmal nocturnal hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS). This targeted approach aims to reduce tissue damage and enhance patient outcomes in these rare and ultra-rare conditions.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary indications for veopoz include gastrointestinal symptoms, hypoalbuminemia, edema, hypogammaglobulinemia, and malnutrition. Gastrointestinal symptoms encompass conditions related to the digestive system, such as nausea, vomiting, diarrhea, or abdominal pain. Veopoz is used to treat gastrointestinal symptoms in patients with conditions such as short bowel syndrome. The distribution channels for Veopoz include hospital pharmacies, retail pharmacies, and online pharmacies. The end users consist of both adult and pediatric patients.
The veopoz market consists of sales of Veopoz (pozelimab) injection and companion medications for autoimmune diseases. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth in the forecast period can be attributed to increasing demand for targeted cancer therapies, growth in prevalence of chronic lymphocytic leukemia (CLL) and follicular lymphoma, expanding adoption of combination therapies, rising healthcare investments in oncology treatments, increasing awareness of personalized medicine, and potential for expanding approvals and indications for veopoz in other cancers. Major trends in the forecast period include advancements in formulation, development of combination therapies, advancements in patient support programs, advancements in cancer research and drug development, and advancements in cancer treatments.
The growing demand for personalized medicine is expected to drive the growth of the Veopoz market. Personalized medicine, also known as precision medicine, is an approach to healthcare that customizes treatment and medical decisions based on the individual characteristics of each patient. This demand is being fueled by advancements in genomics and biotechnology, which enable more targeted and effective treatments that improve patient outcomes and reduce side effects. Veopoz (Pozelimab-bbfg) serves as a personalized medicine by selectively inhibiting complement factor C5 activation, offering a treatment tailored to individual patient profiles, genetic factors, and the severity of diseases involving complement-mediated conditions. For example, in February 2024, the Personalized Medicine Coalition reported that in 2023, personalized medicines accounted for more than one-third of FDA drug approvals, including 16 new treatments for rare diseases, which was more than double the number approved in 2022. As a result, the growing demand for personalized medicine is driving the Veopoz market forward.
A significant trend in the Veopoz market is the expansion of its approved indications, which increases the drug's market reach and therapeutic applications. By broadening its approved indications, the drug can target a larger patient population, further boosting its market share within the biologics and immunology sectors. For instance, in August 2023, Regeneron Pharmaceuticals received FDA approval for Veopoz as the first treatment for CHAPLE disease, an ultra-rare hereditary disorder affecting both adults and children over one year of age. Veopoz is a fully human monoclonal antibody specifically designed to target complement factor C5, aiming to regulate an overactive immune response. This approval marked a significant milestone for Regeneron Pharmaceuticals as their tenth FDA-approved medicine and addressed critical issues related to pre-approval inspections for another product.
In August 2023, Regeneron Pharmaceuticals entered into a partnership with Orsini Specialty Pharmacy, a US-based independent pharmacy that specializes in rare diseases and gene therapies. As part of the agreement, Orsini became the exclusive specialty pharmacy for Veopoz, helping to expand access to this life-changing treatment for patients with ultra-rare conditions who previously had limited options. Through this collaboration, Orsini Specialty Pharmacy plays a crucial role in supporting patients with rare conditions, ensuring they have access to this important treatment.
The key company operating in the veopoz market is Regeneron Pharmaceuticals Inc.
North America was the largest region in the veopoz market in 2024. The regions covered in veopoz report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the veopoz market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Veopoz (pozelimab-bbfg) is a human monoclonal IgG4 antibody that specifically targets and inhibits complement factor C5 in the complement pathway. It helps modulate immune responses in diseases where complement dysregulation plays a critical role, such as paroxysmal nocturnal hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS). This targeted approach aims to reduce tissue damage and enhance patient outcomes in these rare and ultra-rare conditions.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary indications for veopoz include gastrointestinal symptoms, hypoalbuminemia, edema, hypogammaglobulinemia, and malnutrition. Gastrointestinal symptoms encompass conditions related to the digestive system, such as nausea, vomiting, diarrhea, or abdominal pain. Veopoz is used to treat gastrointestinal symptoms in patients with conditions such as short bowel syndrome. The distribution channels for Veopoz include hospital pharmacies, retail pharmacies, and online pharmacies. The end users consist of both adult and pediatric patients.
The veopoz market consists of sales of Veopoz (pozelimab) injection and companion medications for autoimmune diseases. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Veopoz Market Characteristics4. Veopoz Market Trends And Strategies5. Veopoz Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market7. Global Veopoz Pricing Analysis & Forecasts30. Global Veopoz Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Veopoz Market32. Recent Developments In The Veopoz Market
3. Veopoz Market Biologic Drug Characteristics
6. Global Veopoz Growth Analysis And Strategic Analysis Framework
8. Veopoz Market Segmentation
9. Global Veopoz Epidemiology Of Clinical Indications
10. Veopoz Market Regional And Country Analysis
11. Asia-Pacific Veopoz Market
12. China Veopoz Market
13. India Veopoz Market
14. Japan Veopoz Market
15. Australia Veopoz Market
16. South Korea Veopoz Market
17. Western Europe Veopoz Market
18. UK Veopoz Market
19. Germany Veopoz Market
20. France Veopoz Market
21. Eastern Europe Veopoz Market
22. North America Veopoz Market
23. USA Veopoz Market
24. Canada Veopoz Market
25. South America Veopoz Market
26. Middle East Veopoz Market
27. Africa Veopoz Market
28. Veopoz Market Competitive Landscape And Company Profiles
29. Global Veopoz Market Pipeline Analysis
33. Veopoz Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Veopoz Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on veopoz market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for veopoz ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The veopoz market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Indication: Gastrointestinal Symptoms; Hypoalbuminemia; Edema; Hypogammaglobulinemia; Malnutrition2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
3) By End User: Adult Patients; Pediatric Patients
Key Companies Profiled: Regeneron Pharmaceuticals Inc.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Regeneron Pharmaceuticals Inc.
